Table 1. Pharmacokinetic Profiles(a) | ||||||||
Peak
Absorption (hrs) |
Elimination
Half-Life (hrs) |
|
Protein
Binding (%) |
Therapeutic
Range |
||||
children
|
adults
|
|||||||
LI |
1.5 - 4.5
|
24-36
|
24-72
|
0
|
0.6 - 1.2 meq/L
|
|||
CBZ
|
4 - 5
|
6-15
|
10-25
|
70 - 80
|
4 - 12 ug/ml
|
|||
VPA
|
1 - 6
|
4-8
|
10-12
|
80 - 95
|
50 - 120 ug/ml
|
|||
LTG
|
1.4 - 4.8
|
na
|
25
|
55
|
50 - 200 mg/day
|
|||
GBP
|
2 - 3
|
na
|
5-7
|
< 3
|
600 - 3600 mg/day (b)
|
|||
TPM
|
2
|
na
|
21
|
15
|
100 - 400 mg/day (b)
|
|||
(a) Peak serum
levels vary substantially due to preparations available: lithium carbonate
and citrate (1.5-2 hrs), controlled released lithium (4-4.5 hrs); valproic
acid and sodium valproate (1-3 hrs), divalproex Na (4-6 hrs), and divalproex
sprinkle (greater than 4 hrs). |
||||||||
published 2000